Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Garmo

Showing results (61-70 of 261) with videos related to

Pageof 27
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2015
Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancerSean O'Farrell, Hans Garmo, Lars Holmberg, et al.
International Journal of Cancer|July 8, 2022
Susceptibility to SARS-Cov-2 infection and risk for severe COVID-19 in patients with prostate cancer on androgen deprivation therapyRolf Gedeborg, Stacy Loeb, Johan Styrke, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2014
Patterns of androgen deprivation therapies among men diagnosed with localised prostate cancer: a population-based studyMagdalena Lycken, Hans Garmo, Jan Adolfsson, et al.
Acta Oncologica (Stockholm, Sweden)|March 4, 2020
Radical radiotherapy for prostate cancer: patterns of care in Sweden 1998-2016Kerri Beckmann, Hans Garmo, Per Nilsson, et al.
BJU International|September 26, 2018
Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (SPCG-4) studyWalter Cazzaniga, Hans Garmo, David Robinson, et al.
Scandinavian Journal of Urology|February 27, 2025
Improved adherence to prostate cancer guidelines concomitant with public reporting. Nationwide population-based studyAndri Wilberg Orrason, Pietro Scilipoti, Hans Garmo, et al.
Scandinavian Journal of Urology|May 13, 2024
Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostat-ectomy. A nationwide population-based studyPietro Scilipoti, Fredrik Liedberg, Hans Garmo, et al.
European Urology Oncology|May 18, 2019
Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based StudyOskar Bergengren, Hans Garmo, Ola Bratt, et al.
JAMA Network Open|May 17, 2021
Variation in Prostate-Specific Antigen Testing Rates and Prostate Cancer Treatments and Outcomes in a National 20-Year CohortOskar Bergengren, Marcus Westerberg, Lars Holmberg, et al.
European Urology|November 7, 2016
Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate CancerMieke Van Hemelrijck, Hans Garmo, Lars Lindhagen, et al.
Pageof 27

Showing results (61-70 of 261) with videos related to

Sort By:
Pageof 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2015
Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancerSean O'Farrell, Hans Garmo, Lars Holmberg, et al.
International Journal of Cancer|July 8, 2022
Susceptibility to SARS-Cov-2 infection and risk for severe COVID-19 in patients with prostate cancer on androgen deprivation therapyRolf Gedeborg, Stacy Loeb, Johan Styrke, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2014
Patterns of androgen deprivation therapies among men diagnosed with localised prostate cancer: a population-based studyMagdalena Lycken, Hans Garmo, Jan Adolfsson, et al.
Acta Oncologica (Stockholm, Sweden)|March 4, 2020
Radical radiotherapy for prostate cancer: patterns of care in Sweden 1998-2016Kerri Beckmann, Hans Garmo, Per Nilsson, et al.
BJU International|September 26, 2018
Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (SPCG-4) studyWalter Cazzaniga, Hans Garmo, David Robinson, et al.
Scandinavian Journal of Urology|February 27, 2025
Improved adherence to prostate cancer guidelines concomitant with public reporting. Nationwide population-based studyAndri Wilberg Orrason, Pietro Scilipoti, Hans Garmo, et al.
Scandinavian Journal of Urology|May 13, 2024
Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostat-ectomy. A nationwide population-based studyPietro Scilipoti, Fredrik Liedberg, Hans Garmo, et al.
European Urology Oncology|May 18, 2019
Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based StudyOskar Bergengren, Hans Garmo, Ola Bratt, et al.
JAMA Network Open|May 17, 2021
Variation in Prostate-Specific Antigen Testing Rates and Prostate Cancer Treatments and Outcomes in a National 20-Year CohortOskar Bergengren, Marcus Westerberg, Lars Holmberg, et al.
European Urology|November 7, 2016
Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate CancerMieke Van Hemelrijck, Hans Garmo, Lars Lindhagen, et al.
Pageof 27